comparemela.com

Latest Breaking News On - Florida opportunity fund - Page 2 : comparemela.com

HealthSnap Snags $25M to Help Providers Launch & Scale RPM Programs

HealthSnap closed a $25 million Series B funding round led by Sands Capital. The Miami-based company seeks to help providers better care for a rapidly aging and chronically ill population through its remote patient monitoring platform.

United statesSamson magidUnitypoint healthOptimize healthPrisma healthFlorida opportunity fundMontefiore medical centerComcast venturesAcronym venture capitalAsclepius growth capitalFlorida fundersMacdonald venturesTampa general hospitalVirginia cardiovascularWeight lossMedical devices

HealthSnap Closes $25M in Series B Funding

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

United statesScott frederickSamson magidUnitypoint healthPrisma healthFlorida opportunity fundSands capitalComcast venturesAcronym venture capitalFlorida opportunityAsclepius growth capitalFlorida fundersMacdonald venturesManaging partner

FloridaCommerce Recognizes Florida s Economic Achievements in Celebration of Florida Economic Development Week

This week, FloridaCommerce celebrates Florida Economic Development Week

United statesDana youngBeth cicchettiMark wilsonMichael simasAdrienne johnstonRob longKevin carrFlorida economic development councilManufacturing extension partnershipEconomic development weekFlorida opportunity fundFlorida councilAviation aerospaceEconomic developmentFlorida economic development week

Cyrano Therapeutics Raises $9 0M in Series B Financing

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

United statesDelray beachRick geoffrionFlorida opportunity fundCyrano therapeuticsDeepwork capitalLumira ventures

Cyrano Therapeutics Secures $9 0 Million Series B Financing to Advance Clinical Development of CYR-064 for Treatment of Post-Viral Smell Loss

Phase 2 FLAVOR clinical trial currently enrolling 150 patients to assess the safety and effectiveness of CYR-064 in treating patients with chronic smell loss following recovery from a viral infection

United statesDelray beachDave schemeliaRick geoffrionEric reissPrnewswire cyrano therapeutics incFlorida opportunity fundCyrano therapeutics incDeepwork capitalLumira venturesCyrano therapeuticsVenture partnerWork capital

vimarsana © 2020. All Rights Reserved.